Last reviewed · How we verify

NCT03873324

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

Completed Phase 1 Last updated 4 October 2019
What this trial tests

Phase 1 trial testing CPL500036 compound in Healthy Volunteers in 56 participants. Completed in 16 September 2019.

Timeline
20 December 2018
Primary endpoint
16 September 2019
16 September 2019

Quick facts

Lead sponsorCelon Pharma SA
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment56
Start date20 December 2018
Primary completion16 September 2019
Estimated completion16 September 2019
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Celon Pharma SA — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The planned study is to determine the safety and pharmacokinetic properties of CPL500036 compound after single and multiple (two weeks) administration in healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Celon Pharma SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03873324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing